Scholar Rock Completes Enrollment In Phase 2 EMBRAZE Trial For Apitegromab, Investigating Its Ability To Preserve Lean Muscle Mass In Patients On GLP-1 RA Therapy For Obesity; Results Expected In Q2 2025 To Inform Development Of SRK-439 For Cardiometabolic Disorders
Portfolio Pulse from Benzinga Newsdesk
Scholar Rock has completed enrollment for its Phase 2 EMBRAZE trial, which investigates the drug Apitegromab's ability to preserve lean muscle mass in patients undergoing GLP-1 RA therapy for obesity. Results are expected in Q2 2025 and will inform the development of SRK-439 for cardiometabolic disorders.
September 10, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Scholar Rock has completed enrollment for its Phase 2 EMBRAZE trial of Apitegromab, which could impact the company's future in treating obesity and cardiometabolic disorders. Results in Q2 2025 will be crucial for SRK-439 development.
The completion of enrollment in the Phase 2 trial is a significant milestone for Scholar Rock, indicating progress in their clinical development pipeline. However, the results, which are expected in Q2 2025, will be the critical factor influencing the stock's future performance. Until then, the impact on the stock price is likely neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90